Same drug, different outcomes. 🌞 🌒 Time of the day of immunotherapy administration. Too good to be true? Time to wake up your CD8+ lymphocytes!! #LCSM #ASCO25

Proud to see Dr Padda presenting the results of the S1900E. This is yet another example of how we can all come together and conduct national trials in rare subtypes of NSCLC and answer important questions quickly. #lungmap , #ASCO , #FoxChaseCancer

These results will confirm the restriction on nivolumab approval to PD-L1+ve patients in Europe by EU Medicines Agency previously based on EFS data. #ASCO25 #LCSM

🔬Complete pathological response is the strongest predictor of survival in neoadjuvant chemo-IO in NSCLC. 📈5 years OS = 95% (3 non cancer related deaths) 📈5 years DFS = 88% Kudos for the CM-816 investigators. #ASCO25 #LCSM

☢️ Futility of atezolizumab + SBRT in early stage NSCLC. #ASCO25 #lcsm

Dr. Luis Paz-Ares at #ASCO25 with phase III IMforte trial. Adding maintenance lurbinectidin to first-line maintenance atezolizumab in ES #SCLC improves both PFS & OS, meeting primary endpoints. PFS HR 0.54 and OS HR 0.73 with use of lurbinectedin. Value in avoiding attrition.

IMforte: lurbinectedin + atezo maintenance ES-SCLC ✅ ⬆️ mPFS 5.4 v 2.1m, HR 0.54 ✅ ⬆️ mOS 13.2 v 10.6m, HR 0.73 ✅ ⬆️ ORR 19% v 10% 🔺Gr3+ AE 25% v 5% 🔺 Myelosupression, N&V, fatigue 🤔 Active combo, at cost of toxicity 🤔 OS impressive = 16m from diagnosis #LCSM #ASCO25

🚨 #ASCO25: IMforte trial in ES-SCLC ➡️ 1L maintenance: lurbinectedin + atezolizumab vs atezolizumab alone ➡️ Improved OS (median ⬆️ 2.6mo) and PFS (HR 0.55) with combination ➡️ Safety profile 38% G3/G4s vs 22.1% 💥 new standard for extensive small cell #lungcancer? #lcsm

IMForte trial of atezo+- lurbinectidine for pts w ES-SCLC (note no CNS disease) Expected PFS and (as pleasant surprise) quite notable OS benefit linked w fair toxicity/ easy implementation makes me believe that this regimen will immediately Jazz up the ES-SCLC landscape as the

💥 Tarlatamab, an anti-DLL3xCD3 bispecific T-cell engager, improves survival in 2nd line SCLC. Modest effect in ORR, median DoR, and mPFS but ultimately translates in survival with some patients with extraordinary durable control of the disease. 👍 Better tox profile than chemo.

💡 After 2 oral presentations that definitively change the treatment landscape and impacts in survival for patients with ES-SCLC (any of them, if not both, should have been plenary ASCO this year), the key question here is: when will we have access to lurbinectedin and

This thread 🧵👇

Here are the top trials from day 4 of ASCO 2025. Follow us and get the latest #ASCO25 updates: t.ly/7TCD6 #LARVOL #ASCO2025 #CancerResearch #Oncology #ClinicalTrials #CancerData #CancerCare | Paolo Tarantino | Dr Sarah Sammons | Stephen V Liu, MD | Dr. Antonio Calles 🫁🚭 |

🤝 The lurbinectedin + immunotherapy team. The PIs of IMforte, LUPER, and 2SMALL together. #ASCO25 #LCSM SmallCellSMASHERS

CARLOS II, PRINCE OF CLAY 👑 #RolandGarros

⭐️ A hombros de gigantes. Tiempo de despedidas y de legados. Reconocimiento institucional y humano al Dr. Miguel Cuervo, un MÉDICO con mayúsculas. 🏥 #Marañon Sarcomas Hospital Gregorio Marañón #CSUR

Lurbinectedin with atezolizumab maintenance therapy in extensive-stage small-cell lung cancer - The Lancet thelancet.com/journals/lance…

41/2002 #lcsm